Related Experiment Video

Updated: May 16, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

Pharmacotherapy for methicillin-resistant Staphylococcus aureus nosocomial pneumonia

Marisel Segarra-Newnham1, Timothy J Church

  • 1Veterans Affairs Medical Center VAMC, West Palm Beach, FL, USA. marisel.segarra-newnham@va.gov

The Annals of Pharmacotherapy
|December 13, 2012
PubMed
Abstract

Insights

Vancomycin remains the primary treatment for hospital-acquired methicillin-resistant Staphylococcus aureus (MRSA) pneumonia. Linezolid offers an alternative for specific cases, including treatment failure or resistance.

Area of Science:

  • Infectious Diseases
  • Pharmacology
  • Critical Care Medicine

Background:

  • Nosocomial pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) presents a significant therapeutic challenge.
  • Effective pharmacologic options for MRSA pneumonia are limited, necessitating a review of current evidence.

Purpose of the Study:

  • To critically evaluate the evidence supporting available pharmacologic agents for treating nosocomial MRSA pneumonia.
  • To identify the most effective and cost-efficient treatment strategies.

Main Methods:

  • A comprehensive literature search of PubMed (1975-July 2012) was performed.
  • Included studies comprised randomized comparative clinical trials, meta-analyses, and review articles.
  • Observational and in vitro data were incorporated to supplement findings.

Main Results:

  • Vancomycin is the established first-line agent for nosocomial MRSA pneumonia.
  • Linezolid demonstrated comparable efficacy to vancomycin, with potential advantages in certain scenarios.
  • Telavancin showed similar efficacy but is not widely available; other agents have limited evidence for this indication.

Conclusions:

  • Vancomycin is recommended as the initial treatment of choice for most patients due to evidence and cost-effectiveness.
  • Linezolid serves as a viable alternative for patients experiencing vancomycin treatment failure, intolerance, or specific resistance patterns.

More Related Videos

Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria14:04

Biosensor for Detection of Antibiotic Resistant Staphylococcus Bacteria

Published on: May 8, 2013

Related Concept Videos

Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...
Pneumonia IV: Management01:28

Pneumonia IV: Management

The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Acute Pyelonephritis II: Diagnostic Studies and Management01:28

Acute Pyelonephritis II: Diagnostic Studies and Management

Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Atypical Pneumonia01:14

Atypical Pneumonia

Atypical pneumonia, often caused by Mycoplasma pneumoniae, is a form of pulmonary infection that differs from the classical presentation of bacterial pneumonia in both its cause and clinical symptoms. Mycoplasma pneumoniae is a pleomorphic bacterium notable for its lack of a rigid cell wall. This structural characteristic imparts resistance to beta-lactam antibiotics and significantly influences the bacterium’s behavior within the human host.Other pathogens responsible for the disease include...